Senescence is associated with hormonal imbalance and prostatic disorders. Angiogenesis is fundamental for the progression of malignant lesions and is a promising target for prostate cancer treatment. The aim was to characterize matrix metalloproteinase-9 (MMP-9) and insulin-like growth factor receptor-1 (IGFR-1) responses in the prostate during senescence and following antiangiogenic and/or androgen ablation therapies, comparing them to cancer progression features in TRAMP mice. Aged male mice (52-week-old FVB) were submitted to antiangiogenic treatments with SU5416 (6 mg/kg; i.p.) and/or TNP-470 (15 mg/kg; s.c). Finasteride (20 mg/kg; s.c.) was administered alone or associated to both inhibitors. Dorsolateral prostate was collected for light microscopy, and immunohistochemistry and Western blotting collected for MMP-9 and IGFR-1. Senescence led to inflammation and different proliferative lesions in the prostate, as well as to increased MMP-9 and IGFR-1, resembling TRAMP mice prostatic microenvironment. Antiangiogenic therapies promoted recovery and/or interruption of age-associated alterations, presenting differential effects on the molecules studied. SU5416 acted mainly on MMP-9, whereas TNP-470 showed its best influence on IGFR-1 levels. Finasteride administration, alone or in combination with antiangiogenic agents, also resulted in regression of inflammation and neoplastic lesions, besides having a negative modulatory effect on both MMP-9 and IGFR-1. We concluded that stimulated tissue remodeling and proliferative processes during senescence predisposed the prostate to malignant disorders. The combination of different agents was more effective to minimize prostatic imbalance during this period, probably due to the differential action of each drug on factors involved in cell proliferation and extracellular matrix remodeling, resulting in a broader spectrum of effects following the combined treatment. © 2014 Springer-Verlag.1423269284Abdollahi, A., Lipson, K.E., Sckell, A., Zieher, H., Klenke, F., Poerschke, D., Roth, A., Huber, P.E., Combined Therapy with Direct and Indirect Angiogenesis Inhibition Results in Enhanced Antiangiogenic and Antitumor Effects (2003) Cancer Research, 63 (24), pp. 8890-8898Anawalt, B.D., Merriam, G.R., Neuroendocrine aging in men: Andropause and somatopause (2001) Endocrinology and Metabolism Clinics of North America, 30 (3), pp. 647-669. , DOI 10.1016/S0889-8529(05)70206-1Aragon-Ching, J.B., Dahut, W.L., VEGF inhibitors and prostate cancer therapy (2009) Curr Mol Pharmacol, 2, pp. 161-168Bandyopadhyay, A., Wang, L., Lopez-Casillas, F., Mendoza, V., Yeh, I.-T., Sun, L., Systemic administration of a soluble betaglycan suppresses tumor growth, angiogenesis, and matrix metalloproteinase-9 expression in a human xenograft model of prostate cancer (2005) Prostate, 63 (1), pp. 81-90. , DOI 10.1002/pros.20166Banerjee, P.P., Banerjee, S., Lai, J.M., Strandberg, J.D., Zirkin, B.R., Brown, T.R., Age-dependent and lobe-specific spontaneous hyperplasia in the Brown Norway rat prostate (1998) Biology of Reproduction, 59 (5), pp. 1163-1170. , DOI 10.1095/biolreprod59.5.1163Banerjee, P.P., Banerjee, S., Brown, T.R., Increased androgen receptor expression correlates with development of age-dependent, lobe-specific spontaneous hyperplasia of the Brown Norway rat prostate (2001) Endocrinology, 142 (9), pp. 4066-4075. , DOI 10.1210/en.142.9.4066Bergers, G., Brekken, R., McMahon, G., Vu, T.H., Itoh, T., Tamaki, K., Tanzawa, K., Hanahan, D., Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis (2000) Nat Cell Biol, 2, pp. 737-744Berman-Booty, L.D., Sargeant, A.M., Rosol, T.J., Rengel, R.C., Clinton, S.K., Chen, C.S., Kulp, S.K., A review of the existing grading schemes and a proposal for a modified grading scheme for prostatic lesions in TRAMP mice (2012) Toxicol Pathol, 40, pp. 5-17Bianchi-Frias, D., Vakar-Lopez, F., Coleman, I.M., Plymate, S.R., Reed, M.J., Nelson, P.S., The effects of aging on the molecular and cellular composition of the prostate microenvironment (2010) PLoS ONE, , doi:10.1371/journal.pone.0012501Bosland, M.C., Animal models for the study of prostate carcinogenesis (1992) J Cell Biochem Suppl, 16, pp. 89-98Campisi, J., Senescent cells, tumor suppression, and organismal aging: Good citizens, bad neighbors (2005) Cell, 120, pp. 513-522Castronovo, V., Belotti, D., TNP-470 (AGM-1470): Mechanisms of action and early clinical development (1996) Eur J Cancer, 32, pp. 2520-2527Condon, M.S., The role of the stromal microenvironment in prostate cancer (2005) Semin Cancer Biol, 15, pp. 132-137Coppé, J.P., Kauser, K., Campisi, J., Beauséjour, C.M., Secretion of vascular endothelial growth factor by primary human fibroblasts at senescence (2006) J Biol Chem, 281, pp. 29568-29574Cordeiro, R.S., Scarano, W.R., Campos, S.G., Santos, F.C., Vilamaior, P.S., Góes, R.M., Taboga, S.R., Androgen receptor in the Mongolian gerbil ventral prostate: Evaluation during different phases of postnatal development and following androgen blockage (2008) Micron, 39, pp. 1312-1324Delella, F.K., Justulin Jr., L.A., Felisbino, S.L., Finasteride treatment alters MMP-2 and -9 gene expression and activity in the rat ventral prostate (2010) Int J Androl, 33, pp. e114-e122Djavan, B., Waldert, M., Seitz, C., Marberger, M., Insulin-like growth factors and prostate cancer (2001) World Journal of Urology, 19 (4), pp. 225-233Doll, J.A., Reiher, F.K., Crawford, S.E., Pins, M.R., Campbell, S.C., Bouck, N.P., Thrombospondin-I, vascular endothelial growth factor and fibroblast growth factor-2 are key functional regulators of angiogenesis in the prostate (2001) Prostate, 49 (4), pp. 293-305. , DOI 10.1002/pros.10025Ellis, L.M., Takahashi, Y., Liu, W., Shaheen, R.M., Vascular endothelial growth factor in human colon cancer: Biology and therapeutic implications (2000) Oncologist, 5 (SUPPL. 1), pp. 11-15Figg, W.D., Kruger, E.A., Price, D.K., Kim, S., Dahut, W.D., Inhibition of angiogenesis: Treatment options for patients with metastatic prostate cancer (2002) Investigational New Drugs, 20 (2), pp. 183-194. , DOI 10.1023/A:1015626410273Folkman, J., Antiangiogenesis in cancer therapy - endostatin and its mechanisms of action (2006) Exp Cell Res, 312, pp. 594-607Folkman, J.H.P., Hlatky, L., The logic of anti-angiogenic gene therapy (1998) The Development of Gene Therapy, pp. 1-17. , Friedmann T (ed) Cold Spring Harbor Laboratory Press, New YorkFong, T.A.T., Shawver, L.K., Sun, L., Tang, C., App, H., Powell, T.J., Kim, Y.H., McMahon, G., SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types (1999) Cancer Research, 59 (1), pp. 99-106Gennigens, C., Menetrier-Caux, C., Droz, J.P., Insulin-like growth factor (IGF) family and prostate cancer (2006) Crit Rev Oncol Hematol, 58, pp. 124-145Gervaz, P., Scholl, B., Padrun, V., Gillet, M., Growth inhibition of liver metastases by the anti-angiogenic drug TNP-470 (2000) Liver, 20 (2), pp. 108-113. , DOI 10.1034/j.1600-0676.2000.020002108.xGingrich, J.R., Barrios, R.J., Foster, B.A., Greenberg, N.M., Pathologic progression of autochthonous prostate cancer in the TRAMP model (1999) Prostate Cancer and Prostatic Diseases, 2 (2), pp. 70-75Gonzales, G.F., Gasco, M., Malheiros-Pereira, A., Gonzales-Castaneda, C., Antagonistic effect of Lepidium meyenii (red maca) on prostatic hyperplasia in adult mice (2008) Andrologia, 40 (3), pp. 179-185. , DOI 10.1111/j.1439-0272.2008.00834.xGreenberg, N.M., Demayo, F., Finegold, M.J., Medina, D., Tilley, W.D., Aspinall, J.O., Cunha, G.R., Rosen, J.M., Prostate cancer in a transgenic mouse (1995) Proc Natl Acad Sci USA, 92, pp. 3439-3443Grzmil, M., Hemmerlein, B., Thelen, P., Schweyer, S., Burfiend, P., Blockade of the type I IGF receptor expression in human prostate cancer cells inhibits proliferation and invasion, up-regulates IGF binding protein-3 and suppresses MMP-2 expression (2004) Journal of Pathology, 202 (1), pp. 50-59. , DOI 10.1002/path.1492Häggström, S., Torring, N., Moller, K., Jensen, E., Lund, L., Nielsen, J.E., Bergh, A., Damber, J.E., Effects of finasteride on vascular endothelial growth factor (2002) Scand J Urol Nephrol, 36, pp. 182-187Hetzl, A.C., Fávaro, W.J., Billis, A., Ferreira, U., Cagnon, V.H., Steroid hormone receptors, matrix metalloproteinases, insulin-like growth factor, and dystroglycans interactions in prostatic diseases in the elderly men (2012) Microsc Res Tech, 75, pp. 1197-1205Huss, W.J., Barrios, R.J., Greenberg, N.M., SU5416 selectively impairs angiogenesis to induce prostate cancer-specific apoptosis (2003) Mol Cancer Ther, 2, pp. 611-616Huynh, H., Seyam, R.M., Brock, G.B., Reduction of ventral prostate weight by finasteride is associated with suppression of insulin-like growth factor I (IGF-I) and IGF-I receptor genes and with an increase in IGF binding protein 3 (1998) Cancer Research, 58 (2), pp. 215-218Junqueira, L.C.U., Bignolas, G., Brentani, R.R., Picrosirius staining plus polarization microscopy, a specific method for collagen detection in tissue sections (1979) Histochemical Journal, 11 (4), pp. 447-455. , DOI 10.1007/BF01002772Kawada, M., Inoue, H., Arakawa, M., Ikeda, D., Transforming growth factor-beta1 modulates tumor-stromal cell interactions of prostate cancer through insulin-like growth factor-I (2008) Anticancer Research, 28 (2 A), pp. 721-730Kong, D., Li, Y., Wang, Z., Banerjee, S., Sarkar, F.H., Inhibition of angiogenesis and invasion by 3,3′-diindolylmethane is mediated by the NF-kappaB downstream target genes MMP-9 and uPA that regulated bioavailability of VEGF in prostate cancer (2007) Cancer Research, 67 (7), pp. 3310-3319. , DOI 10.1158/0008-5472.CAN-06-4277Koyama, H., Nishizawa, Y., Hosoi, M., Fukumoto, S., Kogawa, K., Shioi, A., Morii, H., The fumagillin analogue TNP-470 inhibits DNA synthesis of vascular smooth muscle cells stimulated by platelet-derived growth factor and insulin- like growth factor-I: Possible involvement of cyclin-dependent kinase 2 (1996) Circulation Research, 79 (4), pp. 757-764Krieg, M., Nass, R., Tunn, S., Effect of aging on endogenous level of 5alpha-dihydrotestosterone, testosterone, estradiol, and estrone in epithelium and stroma of normal and hyperplastic human prostate (1993) Journal of Clinical Endocrinology and Metabolism, 77 (2), pp. 375-381. , DOI 10.1210/jc.77.2.375Krtolica, A., Campisi, J., Cancer and aging: A model for the cancer promoting effects of the aging stroma (2002) International Journal of Biochemistry and Cell Biology, 34 (11), pp. 1401-1414. , DOI 10.1016/S1357-2725(02)00053-5, PII S1357272502000535Lau, K.-M., Tam, N.N.C., Thompson, C., Cheng, R.Y.S., Leung, Y.-K., Ho, S.-M., Age-associated changes in histology and gene-expression profile in the rat ventral prostate (2003) Laboratory Investigation, 83 (5), pp. 743-757London, C.A., Sekhon, H.S., Arora, V., Stein, D.A., Iversen, P.L., Devi, G.R., A novel antisense inhibitor of MMP-9 attenuates angiogenesis, human prostate cancer cell invasion and tumorigenicity (2003) Cancer Gene Therapy, 10 (11), pp. 823-832. , DOI 10.1038/sj.cgt.7700642Lynch, C.C., Matrisian, L.M., Matrix metalloproteinases in tumor-host cell communication (2002) Differentiation, 70 (9-10), pp. 561-573. , DOI 10.1046/j.1432-0436.2002.700909.xMañes, S., Llorente, M., Lacalle, R.A., Gómez-Moutón, C., Kremer, L., Mira, E., Martinez-A, C., The matrix metalloproteinase-9 regulates the insulin-like growth factor-triggered autocrine response in DU-145 carcinoma cells (1999) J Biol Chem, 274, pp. 6935-6945Matsusaka, S., Nakasho, K., Terada, N., Sugihara, A., Tsujimura, T., Takanashi, T., Uematsu, K., Toyosaka, A., Inhibition by an angiogenesis inhibitor, TNP-470, of the growth of a human hepatoblastoma heterotransplanted into nude mice (2000) Journal of Pediatric Surgery, 35 (8), pp. 1198-1204. , DOI 10.1053/jpsu.2000.8726Miele, C., Rochford, J.J., Filippa, N., Giorgetti-Peraldi, S., Van Obberghen, E., Insulin and insulin-like growth factor-I induce vascular endothelial growth factor mRNA expression via different signaling pathways (2000) Journal of Biological Chemistry, 275 (28), pp. 21695-21702. , DOI 10.1074/jbc.M000805200Miller, M.I., Puchner, P.J., Effects of finasteride on hematuria associated with benign prostatic hyperplasia: Long-term follow-up (1998) Urology, 51 (2), pp. 237-240. , DOI 10.1016/S0090-4295(97)00614-6, PII S0090429597006146Minischetti, M., Vacca, A., Ribatti, D., Iurlaro, M., Ria, R., Pellegrino, A., Gasparini, G., Dammacco, F., TNP-470 and recombinant human interferon-alpha2a inhibit angiogenesis synergistically (2000) British Journal of Haematology, 109 (4), pp. 829-837. , DOI 10.1046/j.1365-2141.2000.02087.xMontgomery, D.C., (1991) Design and Analysis of Experiments, 3rd Edn., , Wiley, New YorkMontico, F., Hetzl, A.C., Cândido, E.M., Fávaro, W.J., Cagnon, V.H., Hormonal therapy in the senescence: Prostatic microenvironment structure and adhesion molecules (2011) Micron, 42, pp. 642-655Morrissey, C., Buser, A., Scolaro, J., O'Sullivan, J., Moquin, A., Tenniswood, M., Changes in hormone sensitivity in the ventral prostate of aging Sprague-Dawley rats (2002) Journal of Andrology, 23 (3), pp. 341-351Olumi, A.F., Grossfeld, G.D., Hayward, S.W., Carroll, P.R., Tlsty, T.D., Cunha, G.R., Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium (1999) Cancer Research, 59 (19), pp. 5002-5011Pandini, G., Genua, M., Frasca, F., Vigneri, R., Belfiore, A., Sex steroids upregulate the IGF-1R in prostate cancer cells through a nongenotropic pathway (2009) Ann N Y Acad Sci, 1155, pp. 263-267Pareek, G., Shevchuk, M., Armenakas, N.A., Vasjovic, L., Hochberg, D.A., Basillote, J.B., Fracchia, J.A., The effect of finasteride on the expression of vascular endothelial growth factor and microvessel density: A possible mechanism for decreased prostatic bleeding in treated patients (2003) Journal of Urology, 169 (1), pp. 20-23Plymate, S.R., Tennant, M.K., Culp, S.H., Woodke, L., Marcelli, M., Colman, I., Nelson, P.S., Ware, J.L., Androgen Receptor (AR) expression in AR-Negative prostate cancer cells results in differential effects of DHT and IGF-I on proliferation and AR activity between localized and metastatic tumors (2004) Prostate, 61 (3), pp. 276-290. , DOI 10.1002/pros.20099Prahalada, S., Rhodes, L., Grossman, S.J., Heggan, D., Keenan, K.P., Cukierski, M.A., Hoe, C.M., Van Zwieten, M.J., Morphological and hormonal changes in the ventral and dorsolateral prostatic lobes of rats treated with finasteride, a 5-alpha reductase inhibitor (1998) Prostate, 35 (3), pp. 157-164. , DOI 10.1002/(SICI)1097-0045(19980515)35:3<157::AIDPrins, G.S., Jung, M.H., Vellanoweth, R.L., Chatterjee, B., Roy, A.K., Age-dependent expression of the androgen receptor gene in the prostate and its implication in glandular differentiation and hyperplasia (1996) Developmental Genetics, 18 (2), pp. 99-106. , DOI 10.1002/(SICI)1520-6408(1996)18:2<99::AID-DVG2Retter, A.S., Figg, W.D., Dahut, W.L., The Combination of Antiangiogenic and Cytotoxic Agents in the Treatment of Prostate Cancer (2003) Clinical Prostate Cancer, 2 (3), pp. 153-159Reynolds, A.R., Kyprianou, N., Growth factor signalling in prostatic growth: Significance in tumour development and therapeutic targeting (2006) British Journal of Pharmacology, 147 (SUPPL. 2), pp. S144-S152. , DOI 10.1038/sj.bjp.0706635, PII 0706635Roy-Burman, P., Wu, H., Powell, W.C., Hagenkord, J., Cohen, M.B., Genetically defined mouse models that mimic natural aspects of human prostate cancer development (2004) Endocrine-Related Cancer, 11 (2), pp. 225-254. , DOI 10.1677/erc.0.0110225Rullis, I., Shaeffer, J.A., Lilien, O.M., Incidence of prostatic carcinoma in the elderly (1975) Urology, 6, pp. 295-297Ryan, C.J., Haqq, C.M., Simko, J., Nonaka, D.F., Chan, J.M., Weinberg, V., Small, E.J., Goldfine, I.D., Expression of insulin-like growth factor-1 receptor in local and metastatic prostate cancer (2007) Urologic Oncology: Seminars and Original Investigations, 25 (2), pp. 134-140. , DOI 10.1016/j.urolonc.2006.07.019, PII S1078143906002419, Reconstructive Aspects of Urologic OncologySaikali, Z., Setya, H., Singh, G., Persad, S., Role of IGF-1/IGF-1R in regulation of invasion in DU145 prostate cancer cells (2008) Cancer Cell Int, 8, p. 10Sin, N., Meng, L., Wang, M.Q.W., Wen, J.J., Bornmann, W.G., Crews, C.M., The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2 (1997) Proceedings of the National Academy of Sciences of the United States of America, 94 (12), pp. 6099-6103. , DOI 10.1073/pnas.94.12.6099Sprenger, C.C., Plymate, S.R., Reed, M.J., Extracellular influences on tumour angiogenesis in the aged host (2008) British Journal of Cancer, 98 (2), pp. 250-255. , DOI 10.1038/sj.bjc.6604144, PII 6604144Strieth, S., Eichhorn, M.E., Sutter, A., Jonczyk, A., Berghaus, A., Dellian, M., Antiangiogenic combination tumor therapy blocking alpha(v)-integrins and VEGF-receptor-2 increases therapeutic effects in vivo (2006) Int J Cancer, 119, pp. 423-431Sweeney, P., Karashima, T., Kim, S.-J., Kedar, D., Mian, B., Huang, S., Baker, C., Dinney, C.P.N., Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production (2002) Clinical Cancer Research, 8 (8), pp. 2714-2724Takamoto, T., Sasaki, M., Kuno, T., Tamaki, N., Flk-1 specific kinase inhibitor (SU5416) inhibited the growth of GS-9L glioma in rat brain and prolonged the survival (2001) Kobe Journal of Medical Sciences, 47 (4), pp. 181-191Thompson, I.M., Goodman, P.J., Tangen, C.M., Lucia, M.S., Miller, G.J., Ford, L.G., Lieber, M.M., Coltman Jr., C.A., The influence of finasteride on the development of prostate cancer (2003) New England Journal of Medicine, 349 (3), pp. 215-224. , DOI 10.1056/NEJMoa030660Thum, T., Hoeber, S., Froese, S., Klink, I., Stichtenoth, D., Galuppo, P., Jakob, M., Bauersachs, J., Age-dependent impairment of endothelial progenitor cells is corrected by growth hormone mediated increase of insulin-like growth factor-1 (2007) Circ Res, 100, pp. 434-443Tsukamoto, S., Akaza, H., Imada, S., Koiso, K., Shirai, T., Ideyama, Y., Kudo, M., Chemoprevention of rat prostate carcinogenesis by use of finasteride or casodex (1995) J Natl Cancer Inst, 87, pp. 842-843Turk, B.E., Griffith, E.C., Wolf, S., Biemann, K., Chang, Y.H., Liu, J.O., Selective inhibition of amino-terminal methionine processing by TNP-470 and ovalicin in endothelial cells (1999) Chem Biol, 6, pp. 823-833Tutrone Jr., R.F., Ball, R.A., Ornitz, D.M., Leder, P., Richie, J.P., Benign prostatic hyperplasia in a transgenic mouse: A new hormonally sensitive investigatory model (1993) J Urol, 149, pp. 633-699Tuxhorn, J.A., Ayala, G.E., Rowley, D.R., Reactive stroma in prostate cancer progression (2001) Journal of Urology, 166 (6), pp. 2472-2483Tuxhorn, J.A., Ayala, G.E., Smith, M.J., Smith, V.C., Dang, T.D., Rowley, D.R., Reactive stroma in human prostate cancer: Induction of myofibroblast phenotype and extracellular matrix remodeling (2002) Clinical Cancer Research, 8 (9), pp. 2912-2923Van Moorselaar, R.J.A., Voest, E.E., Angiogenesis in prostate cancer: Its role in disease progression and possible therapeutic approaches (2002) Molecular and Cellular Endocrinology, 197 (1-2), pp. 239-250. , DOI 10.1016/S0303-7207(02)00262-9, PII S0303720702002629Wang, Y.Z., Wong, Y.C., Sex hormone-induced prostatic carcinogenesis in the noble rat: The role of insulin-like growth factor-1 (IGF-1) and vascular endothelial growth factor (VEGF) in the development of prostate cancer (1998) Prostate, 35 (3), pp. 165-177. , DOI 10.1002/(SICI)1097-0045(19980515)35:3<165::AIDYoshiji, H., Harris, S.R., Thorgeirsson, U.P., Vascular endothelial growth factor is essential for initial but not continued in vivo growth of human breast carcinoma cells (1997) Cancer Research, 57 (18), pp. 3924-3928Zar, J.H., (1999) Biostatistical Analysis, , Prentice Hall Upper, New Jersey